Literature DB >> 34905235

Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.

Shailendra K Saxena1,2,3, Swatantra Kumar1,2, Saniya Ansari1, Janusz T Paweska2,4, Vimal K Maurya1, Anil K Tripathi1, Ahmed S Abdel-Moneim2,5,6.   

Abstract

As the latest identified novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC), the influence of Omicron on our globe grows promptly. Compared with the last VOC (Delta variant), more mutations were identified, which may address the characteristics of Omicron. Considering these crucial mutations and their implications including an increase in transmissibility, COVID-19 severity, and reduction of efficacy of currently available diagnostics, vaccines, and therapeutics, Omicron has been classified as one of the VOC. Notably, 15 of these mutations reside in the receptor-binding domain of spike glycoprotein, which may alter transmissibility, infectivity, neutralizing antibody escape, and vaccine breakthrough cases of COVID-19. Therefore, our present study characterizes the mutational hotspots of the Omicron variant in comparison with the Delta variant of SARS-CoV-2. Furthermore, detailed information was analyzed to characterize the global perspective of Omicron, including transmission dynamic, effect on testing, and immunity, which shall promote the progress of the clinical application and basic research. Collectively, our data suggest that due to continuous variation in the spike glycoprotein sequences, the use of coronavirus-specific attachment inhibitors may not be the current choice of therapy for emerging SARS-CoV-2 VOCs. Hence, we need to proceed with a sense of urgency in this matter.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  B.1.1.529; COVID-19; Delta; Omicron; SARS-CoV-2; receptor-binding domain; variants of concern

Mesh:

Substances:

Year:  2022        PMID: 34905235     DOI: 10.1002/jmv.27524

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  73 in total

1.  SARS-CoV-2 variants and vaccination.

Authors:  Yang Liu; Jianying Liu; Pei-Yong Shi
Journal:  Zoonoses (Burlingt)       Date:  2022-02-08

2.  Development of a new antigen-based microarray platform for screening and detection of human IgG antibodies against SARS-CoV-2.

Authors:  Sindy Burgold-Voigt; Elke Müller; David Zopf; Stefan Monecke; Sascha D Braun; Katrin Frankenfeld; Michael Kiehntopf; Sebastian Weis; Thomas Schumacher; Mathias W Pletz; Ralf Ehricht
Journal:  Sci Rep       Date:  2022-05-16       Impact factor: 4.996

3.  Identification of a novel immune-inflammatory signature of COVID-19 infections, and evaluation of pharmacokinetics and therapeutic potential of RXn-02, a novel small-molecule derivative of quinolone.

Authors:  Bashir Lawal; Yu-Cheng Kuo; Maryam Rachmawati Sumitra; Alexander T H Wu; Hsu-Shan Huang
Journal:  Comput Biol Med       Date:  2022-07-11       Impact factor: 6.698

4.  Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.

Authors:  Nawal Al Kaabi; Yun Kai Yang; Jing Zhang; Ke Xu; Yu Liang; Yun Kang; Ji Guo Su; Tian Yang; Salah Hussein; Mohamed Saif ElDein; Shuai Shao; Sen Sen Yang; Wenwen Lei; Xue Jun Gao; Zhiwei Jiang; Hui Wang; Meng Li; Hanadi Mekki Mekki; Walid Zaher; Sally Mahmoud; Xue Zhang; Chang Qu; Dan Ying Liu; Jing Zhang; Mengjie Yang; Islam Eltantawy; Peng Xiao; Zhao Nian Wang; Jin Liang Yin; Xiao Yan Mao; Jin Zhang; Ning Liu; Fu Jie Shen; Liang Qu; Yun Tao Zhang; Xiao Ming Yang; Guizhen Wu; Qi Ming Li
Journal:  Signal Transduct Target Ther       Date:  2022-06-06

5.  The impact of the Omicron epidemic on the health behavior in Cape Town, South Africa.

Authors:  Xiao-Qing Lin; Li Lv; Yan Chen; He-Dan Chen; Mei-Xian Zhang; Tao-Hsin Tung; Jian-Sheng Zhu
Journal:  One Health       Date:  2022-05-05

Review 6.  Antiviral Characterization of Advanced Materials: Use of Bacteriophage Phi 6 as Surrogate of Enveloped Viruses Such as SARS-CoV-2.

Authors:  Ángel Serrano-Aroca
Journal:  Int J Mol Sci       Date:  2022-05-10       Impact factor: 6.208

7.  Analytic modeling and risk assessment of aerial transmission of SARS-CoV-2 virus through vaping expirations in shared micro-environments.

Authors:  Roberto A Sussman; Eliana Golberstein; Riccardo Polosa
Journal:  Environ Sci Pollut Res Int       Date:  2022-06-27       Impact factor: 5.190

8.  Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial.

Authors:  Rongrong Zou; Ling Peng; Dan Shu; Lei Zhao; Jianfeng Lan; Guoyu Tan; Jinghan Peng; Xiangyi Yang; Miaona Liu; Chenhui Zhang; Jing Yuan; Huxiang Wang; Song Li; Hongzhou Lu; Wu Zhong; Yingxia Liu
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

9.  Evaluation of the Panbio COVID-19 Antigen Rapid Diagnostic Test in Subjects Infected with Omicron Using Different Specimens.

Authors:  Rafael Mello Galliez; Larissa Bomfim; Debora Souza Faffe; Amilcar Tanuri; Diana Mariani; Isabela de Carvalho Leitão; Anna Carla Pinto Castiñeiras; Cassia Cristina Alves Gonçalves; Bianca Ortiz da Silva; Pedro Henrique Cardoso; Monica Barcelos Arruda; Patricia Alvarez; Rodrigo Brindeiro; Victor Akira Ota; Débora Gomes Marins Rodrigues; Luciana Jesus da Costa; Orlando da Costa Ferreira; Terezinha Marta Pereira Pinto Castiñeiras
Journal:  Microbiol Spectr       Date:  2022-06-02

Review 10.  Omicron - The new SARS-CoV-2 challenge?

Authors:  A Lino; M A Cardoso; P Martins-Lopes; H M R Gonçalves
Journal:  Rev Med Virol       Date:  2022-04-21       Impact factor: 11.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.